Literature DB >> 23588338

Predictors for bacteremia in febrile sickle cell disease children in the post-7-valent pneumococcal conjugate vaccine era.

Todd P Chang1, Worapant Kriengsoontorkij, Linda S Chan, Vincent J Wang.   

Abstract

OBJECTIVES: The objective of this study was to determine the incidence of bacteremia in febrile sickle cell disease (SCD) children before and after the 7-valent pneumococcal vaccine (PCV7), and to determine clinical factors associated with bacteremia following PCV7. PATIENTS AND METHODS: We reviewed all febrile events in SCD children from 1993 to 2009 at a tertiary care pediatric center, comparing general bacteremia and pneumococcal bacteremia incidence for 3 time periods around the PCV7. Univariate analysis and stepwise logistic regression identified clinical factors most associated with bacteremia in this population.
RESULTS: Of 466 SCD children identified, there were 2504 febrile events. We found 84 cases of bacteremia; 8 were pneumococcal. The general bacteremia incidence decreased significantly from 5.60% to 2.44% (P<0.001) over time. Pneumococcal bacteremia incidence did not decrease (P=0.13). Following PCV7, we identified 4 significant independent risk factors associated with general bacteremia: the presence of a central venous line, higher absolute band count, toxic appearance, and older age.
CONCLUSIONS: In febrile SCD children, the incidence of general bacteremia decreased over time. No decrease in pneumococcal bacteremia was found. The presence of a central venous line, absolute band count, clinical appearance, and age may help predict bacteremia in this population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588338     DOI: 10.1097/MPH.0b013e31828ac9e2

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.

Authors:  Marianne E Yee; Kristina W Lai; Nitya Bakshi; Joanna K Grossman; Preeti Jaggi; Alexander Mallis; Yun F Wang; Robert C Jerris; Peter A Lane; Inci Yildirim
Journal:  Pediatrics       Date:  2022-01-01       Impact factor: 7.124

2.  Outcomes of febrile events in pediatric patients with sickle cell anemia.

Authors:  Krishnaveni Sirigaddi; Inmaculada Aban; Amelia Jantz; Brandi M Pernell; Lee M Hilliard; Smita Bhatia; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-01       Impact factor: 3.167

3.  Risk-score based strategy to minimize antibiotic exposure in children with sickle cell disease and fever.

Authors:  Elena María Rincón-López; María Luisa Navarro Gómez; Teresa Hernández-Sampelayo Matos; David Aguilera-Alonso; Eva Dueñas Moreno; José María Bellón Cano; Jesús Saavedra-Lozano; María Del Mar Santos Sebastián; Marina García Morín; Cristina Beléndez Bieler; Jorge Lorente Romero; Elena Cela de Julián
Journal:  Infection       Date:  2021-10-01       Impact factor: 7.455

4.  Deciphering risk factors for blood stream infections, bacteria species and antimicrobial resistance profiles among children under five years of age in North-Western Tanzania: a multicentre study in a cascade of referral health care system.

Authors:  J Seni; A A Mwakyoma; F Mashuda; R Marando; M Ahmed; R DeVinney; J D D Pitout; S E Mshana
Journal:  BMC Pediatr       Date:  2019-01-26       Impact factor: 2.125

5.  A Quality Initiative to Decrease Time to Antibiotics in Children with Sickle Cell Disease and Fever.

Authors:  Christopher McKinney; Amy Caruso-Brown; Kathleen Montgomery; Anne Gillespie; Rebecca Coughlin; Dawn Law; Anna Brouwer; Lauren Tytler; Joanne Hilden; Rachelle Nuss
Journal:  Pediatr Qual Saf       Date:  2020-01-10

6.  Interleukin 6 as a marker of severe bacterial infection in children with sickle cell disease and fever: a case-control study.

Authors:  Elena María Rincón-López; María Luisa Navarro Gómez; Teresa Hernández-Sampelayo Matos; David Aguilera-Alonso; Eva Dueñas Moreno; Jesús Saavedra-Lozano; Begoña Santiago García; María Del Mar Santos Sebastián; Marina García Morín; Cristina Beléndez Bieler; Jorge Lorente Romero; Elena Cela de Julián
Journal:  BMC Infect Dis       Date:  2021-08-03       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.